Latest research on Xarelto

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.

Xarelto side effects

The FDA-Clinical Pharmacology Biopharmaceutics Review(s) of Xarelto also mentions that a two-fold increase in exposure due to intrinsic and extrinsic factors will increase the risk of major bleeding by 50% [17]. [source, 2015]
The numbers compare to 750 adverse events and 58 deaths throughout all of the previous year, indicating that the increase tracked with the rise in use of Xarelto, which had reportedly increased 240% after just 1 1/2 years on the market. [source, 2015]
The European prescribing information states that “in patients with moderate renal impairment (creatinine clearance 30–49 mL/min) concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations, Xarelto [rivaroxaban] is to be used with caution”.2 [source, 2014]
Taken together, the results of dose-finding studies of BAY 59-7939 lead to an interesting observation: it appears that higher doses increase the frequency of major postoperative bleeding events and are less effective in preventing venous thromboembolism compared to moderate doses. [source, 2007]